The shadow of generic competition has repeatedly loomed around copyright’s famous drug, Viagra, sparking questions about the outlook of related medicinal holdings. While early periods saw impressive gains, the patent lapse has opened the way for discounted alternatives, likely diminishing earnings and presenting a genuine hazard for stakeholders